All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelium cells
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelial cells
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
OpRegen is an investigational cell therapy consisting of retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: NM141
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
TTHX1114, administered by intracameral injection, is currently undergoing a Phase 1/2 clinical study to assess its safety and ability to regenerate corneal endothelial cells lost due to corneal endothelial dystrophies, including Fuchs endothelial corneal dystrophy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IVMED-80
Therapeutic Area: Ophthalmology Product Name: IVMED-80
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
IVMED-80 is a proprietary non-surgical, non-invasive, disease modifying intervention with FDA orphan designation that upregulates lysyl oxidase (LOX) and induces corneal crosslinking pharmacologically.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AR-15512
Therapeutic Area: Ophthalmology Product Name: AVX012
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The active ingredient in AR-15512 is a potent and selective agonist of the TRPM8 cold thermoreceptor ion channel that regulates tear production and blink rate. The acceptance of the IND for AR-15512 marks the first clinical-stage dry eye product candidate for Aerie.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IVMED-80
Therapeutic Area: Ophthalmology Product Name: IVMED-80
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: National Eye Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series B Financing August 25, 2020
Details:
These investments will be used to advance the clinical development programs for the treatment of keratoconus and pediatric high myopia and adult low myopia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: NM141
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
The Phase 1/2 trial (“INTREPID”) is designed to evaluate TTHX1114’s safety and ability to stimulate the regeneration of corneal endothelial cells lost due to CED when administered by intracameral (back of the cornea) injection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDIT-101
Therapeutic Area: Ophthalmology Product Name: AGN-151587
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination August 06, 2020
Details:
Etidas has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelium cell transplant therapy
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Israel Innovation Authority
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 06, 2020
Details:
As a result of continued clinical progress, the Israel Innovation Authority has extended its previously awarded development grant in support of OpRegen®, Company’s retinal pigment epithelium cell transplant therapy in development for the treatment of dry AMD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelial cells
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
Details:
The company has restarted patient enrollment in a Phase 1/2a study of OpRegen a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
